Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: gattei v. Leukemia. 2006 Oct;20(10):1783-9. doi: 10.1038/sj.leu.2404313. Epub 2006 Jul 13. Leukemia. 2006. PMID: 16838027
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias.
Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E, Rupolo M, Berretta M, Degan M, Russo S, Tamburini A, Maurillo L, Del Principe MI, Postorino M, Amadori S, Gattei V. Buccisano F, et al. Among authors: gattei v. Br J Haematol. 2004 Apr;125(2):203-12. doi: 10.1111/j.1365-2141.2004.04883.x. Br J Haematol. 2004. PMID: 15059143 Free article.
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.
Zucchetto A, Sonego P, Degan M, Bomben R, Dal Bo M, Russo S, Attadia V, Rupolo M, Buccisano F, Steffan A, Del Poeta G, Pucillo C, Colombatti A, Campanini R, Gattei V. Zucchetto A, et al. Among authors: gattei v. J Immunol Methods. 2005 Oct 20;305(1):20-32. doi: 10.1016/j.jim.2005.07.004. Epub 2005 Aug 8. J Immunol Methods. 2005. PMID: 16198366
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianní L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S. Del Poeta G, et al. Among authors: gattei v. Cancer. 2005 Dec 15;104(12):2743-52. doi: 10.1002/cncr.21535. Cancer. 2005. PMID: 16284990 Free article. Clinical Trial.
288 results